In a nutshell This study looked at a combination of chemotherapy and an antiangiogenic drug bevacizumab to treat patients with advanced non-small-cell lung cancer. The authors concluded that this combination may have potential to control cancer in these patients. Some background Despite the major advances in cancer treatments in recent years,...
Read More
In a nutshell This study investigated respiratory side effects in patients with non-Hodgkin’s lymphoma (NHL) who received chemotherapy containing rituximab (Rituxan). This study concluded that these side effects are common and associated with increased mortality in these patients. Some background Non-Hodgkin’s lymphoma patients treated...
Read MoreIn a nutshell This study investigated the safety and effectiveness of rituximab (Rituxan) plus bortezomib (Velcade) for patients with mantle cell lymphoma after stem cell transplant. This study concluded that this combination is a safe and effective regimen in these patients. Some background The standard treatment for younger patients with mantle cell...
Read More
In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read More
In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read More
In a nutshell This study examined the effect of graft versus host disease on relapse rates in children with acute leukemia. This study concluded that graft versus host disease may protect against relapse, but they did not see an effect on survival. Some background One complication following an allogeneic stem cell transplant (transplant using donor...
Read More
In a nutshell This study was a systematic review (looking at all available and relevant evidence) of the safety and effectiveness of different treatment options for elderly patients with acute myeloid leukemia (AML). The study found that azacitidine (Vidaza) was safe and more effective than intensive chemotherapy in these patients. Some...
Read MoreIn a nutshell This study aimed to determine whether differences in side effects reported over time in patients who had surgery or radiotherapy varied by risk group. This study found that for men with low-risk prostate cancer, radiotherapy was associated with higher sexual function scores at 3 years than surgery;...
Read More
In a nutshell This study aimed to compare quality of life between patients with metastatic prostate cancer who were treated with androgen deprivation therapy (ADT) and docetaxel and those who were treated with ADT alone. This study found that ADT and docetaxel was associated with statistically worse QOL at 3 months. However, QOL was better...
Read MoreIn a nutshell This study aimed to investigate the effects of chemotherapy alone or chemotherapy plus anti-PD1 therapy in patients with relapsing/refractory (RR) Hodgkin's Lymphoma. The main finding was that anti-PD1 treatment enhances the effectiveness of chemotherapy in these patients. Some background Stem cell transplant (SCT) and...
Read More
In a nutshell This study looked at the effect of treosulfan combined with fludarabine (Fludara) and low-dose radiotherapy in the treatment of children with acute myeloid leukemia (AML). The researchers found that treosulfan combined with these therapies improved successful graft transplantation in the treatment of AML. Some background Acute myeloid...
Read More
In a nutshell This study aimed to investigate the side effects of tyrosine kinase inhibitors and their impact on outcomes in chronic-phase chronic myeloid leukemia patients. This study concluded that severe side effects from tyrosine kinase inhibitors can cause decreased survival rates in these patients. Some background Tyrosine kinase inhibitors...
Read More
